Tridacaine XL 50 mg/g
Lidocaine · PATCH · Trifluent Pharma LLC
Tridacaine XL is a patch containing lidocaine at 50 mg/g, taken topical. Manufactured by Trifluent Pharma LLC.
Key Facts
- Brand Name
- Tridacaine XL
- Generic Name
- Lidocaine
- NDC Code (Product)
73352-845- Manufacturer
- Trifluent Pharma LLC
- Strength
- 50 mg/g
- Dosage Form
- PATCH
- Route
- TOPICAL
- Marketing Status
- Application #
- ANDA209190
- Drug Class
- Amide Local Anesthetic [EPC]; Antiarrhythmic [EPC]
- Marketing Start
- 09/20/2024
Recall History
No Recall HistoryFull Prescribing Information
Indications & Usage
INDICATION AND USAGE Lidocaine patch 5% is indicated for relief of pain associated with post-herpetic neuralgia. It should be applied only to intact skin.
Dosage & Administration
DOSAGE AND ADMINISTRATION Apply lidocaine patch 5% to intact skin to cover the most painful area. Apply the prescribed number of patches (maximum of 3), only once for up to 12 hours within a 24-hour period. Patches may be cut into smaller sizes with scissors prior to removal of the release liner. (See HANDLING AND DISPOSAL ) Clothing may be worn over the area of application. Smaller areas of treatment are recommended in a debilitated patient, or a patient with impaired elimination. If irritation or a burning sensation occurs during application, remove the patch(es) and do not reapply until the irritation subsides. When lidocaine patch 5% is used concomitantly with other products containing local anesthetic agents, the amount absorbed from all formulations must be considered. Lidocaine patch 5% may not stick if it gets wet. Avoid contact with water, such as bathing, swimming or showering.
Warnings
WARNINGS Risk of Methemoglobinemia Cases of methemoglobinemia have been reported in association with local anesthetic use. Although all patients are at risk for methemoglobinemia, patients with glucose-6-phosphate dehydrogenase deficiency, congenital or idiopathic methemoglobinemia, cardiac or pulmonary compromise, infants under 6 months of age, and concurrent exposure to oxidizing agents or their metabolites are more susceptible to developing clinical manifestations of the condition. If local anesthetics must be used in these patients, close monitoring for symptoms and signs of methemoglobinemia is recommended. Signs of methemoglobinemia may occur immediately or may be delayed some hours after exposure, and are characterized by a cyanotic skin discoloration and/or abnormal coloration of the blood. Methemoglobin levels may continue to rise; therefore, immediate treatment is required to avert more serious central nervous system and cardiovascular adverse effects including seizures, coma, arrhythmias, and death. Discontinue lidocaine and any other oxidizing agents. Depending on the severity of the signs and symptoms, patients may respond to supportive care, i.e., oxygen therapy, hydr…
Contraindications
CONTRAINDICATIONS Lidocaine patch 5% is contraindicated in patients with a known history of sensitivity to local anesthetics of the amide type, or to any other component of the product.
Drug Interactions
Drug Interactions Antiarrhythmic Drugs Lidocaine patch 5% should be used with caution in patients receiving Class I antiarrhythmic drugs (such as tocainide and mexiletine) since the toxic effects are additive and potentially synergistic. Local Anesthetics When lidocaine patch 5% is used concomitantly with other products containing local anesthetic agents, the amount absorbed from all formulations must be considered. Drugs That May Cause Methemoglobinemia When Used with Lidocaine Patch 5% Patients who are administered local anesthetics are at increased risk of developing methemoglobinemia when concurrently exposed to the following drugs, which could include other local anesthetics: Examples of Drugs Associated with Methemoglobinemia: Class Examples Nitrates/Nitrites nitric oxide, nitroglycerin, nitroprusside, nitrous oxide Local anesthetics articaine, benzocaine, bupivacaine, lidocaine, mepivacaine, prilocaine, procaine, ropivacaine, tetracaine Antineoplastic agents cyclophosphamide, flutamide, hydroxyurea, ifosfamide, rasburicase Antibiotics dapsone, nitrofurantoin, para-aminosalicylic acid, sulfonamides Antimalarials chloroquine, primaquine Anticonvulsants phenobarbital, phenytoin…
Adverse Reactions
ADVERSE REACTIONS Application Site Reactions During or immediately after treatment with lidocaine patch 5%, the skin at the site of application may develop blisters, bruising, burning sensation, depigmentation, dermatitis, discoloration, edema, erythema, exfoliation, irritation, papules, petechia, pruritus, vesicles, or may be the locus of abnormal sensation. These reactions are generally mild and transient, resolving spontaneously within a few minutes to hours. Allergic Reactions Allergic and anaphylactoid reactions associated with lidocaine, although rare, can occur. They are characterized by angioedema, bronchospasm, dermatitis, dyspnea, hypersensitivity, laryngospasm, pruritus, shock, and urticaria. If they occur, they should be managed by conventional means. The detection of sensitivity by skin testing is of doubtful value. Other Adverse Events Due to the nature and limitation of spontaneous reports in postmarketing surveillance, causality has not been established for additional reported adverse events including: Asthenia, confusion, disorientation, dizziness, headache, hyperesthesia, hypoesthesia, lightheadedness, metallic taste, nausea, nervousness, pain exacerbated, paresth…
Frequently Asked Questions
What is Tridacaine XL used for?
Tridacaine XL contains Lidocaine. It is a patch taken topical. Consult your doctor for specific uses.
Is Tridacaine XL a controlled substance?
Tridacaine XL is not classified as a controlled substance by the DEA.
What is the generic name for Tridacaine XL?
The generic name for Tridacaine XL is Lidocaine. There are 12 other brand versions of Lidocaine.
What is the NDC code for Tridacaine XL 50 mg/g?
The NDC (National Drug Code) for Tridacaine XL 50 mg/g is 73352-845, listed by Trifluent Pharma LLC.
Other Lidocaine Brands
See all →- MAXOCAINE Topical Anesthetic Anorectal50 mg/mL72188-076
- MAXOCAINE Lidocaine Hemp Oil Topical Analgesic40 mg/mL72188-188
- LIDOCAINE50 mg/g72189-211
- INSTA RELIEF DM40 mg/mL72465-600
- Lidocaine Hydrochloride10 mg/mL72603-350
- Hemorrhoid Master40 mg/g72654-002
- DCH Nerve Pain Relief Roll-On4 g/100g72839-014
- DCH Pain Relief Roll-On4 g/100g72839-087
- FIRST SHIELD20 mg/mL72976-004
- Lidocaine Hydrochloride10 mg/mL73293-0001
Not medical advice. Always consult your doctor or pharmacist before making any medication decisions.
Data from openFDA · Public domain (CC0 1.0)